Targeting IRAK4 in Chronic Lymphocytic Leukemia | NCT07741695

NCT07741695

Overview

NCT ID: NCT07741695
Lead Sponsor: IRCCS San RaffaeleOTHER
Official Title: Targeting IRAK4 in Chronic Lymphocytic Leukemia
Brief Summary: Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Peripheral blood sample collection

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Aug 3, 2026Actual
Start Date: Sep 2026Estimated
Primary Completion Date: Sep 2027Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Age ≥18 years

Diagnosis of CLL

Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

1) Participant is unable or unwilling to provide informed consent for participation in the study

Study Plan

Study Type: Observational
Phase: No data available
Enrollment: 50Estimated
Primary Purpose: No data available
Allocation: No data available
Interventional Model: No data available
Masking: No data available

Contacts and Locations

Central Contacts: Paolo Ghia, MD, PhDContact
ghia.paolo@hsr.it+390226434797

Similar Studies

Participant Group/Arms

Study cohort

Collection of peripheral blood (up to 50 ml) for the analysis of the biological activity of IRAK4 Chimeric Degradation Activation Compound (CDAC) in purified CLL B cells, assessed by changes in proliferation, apoptosis, and signaling pathway activation following in vitro treatment.

Procedure: Peripheral blood sample collection